Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Clopidogrel loading offers little added benefit for stenosis patients pre-TAVI

P2Y12 inhibitor initiation with clopidogrel using a loading dose (LD) is no more effective in reducing ischemic events or adverse outcomes in transcatheter aortic valve implantation (TAVI) patients than initiating the therapy without a loading dose, according to research published in the American Journal of Cardiology Feb. 10.

Thumbnail

Telerehab as effective as clinical therapy for restoring functionality after stroke

Home-based telerehabilitation is just as effective as traditional rehab for restoring arm function in stroke survivors, according to late-breaking science presented at this year’s American Stroke Association International Stroke Conference in Honolulu.

Thumbnail

Under-table shields reduce radiation to operators during PCI, angiography

Placing homemade shields under the angiographic table during percutaneous coronary procedures cut operators’ exposure to radiation at the pelvic level by a median of 72 percent, according to a single-center study in Circulation: Cardiovascular Interventions.

His-optimized CRT improves electrical resynchronization in advanced HF patients

His-optimized cardiac resynchronization therapy successfully narrowed QRS duration, improved left ventricular (LV) ejection fraction and heightened functionality in 27 patients with advanced heart failure (HF), according to a study published in Circulation: Arrhythmia and Electrophysiology.

Thumbnail

Now that it’s guideline-endorsed, how should clinicians use CAC testing?

“Rather than bringing in many additional statin candidates, this testing should serve as a decision aid to ‘de-risk’ certain patients and distinguish those who may benefit from preventive pharmacologic therapies," Johns Hopkins researchers wrote in the Annals of Internal Medicine.

Thumbnail

Andexanet holds up as antidote for factor Xa inhibitors

Andexanet alfa (Andexxa), the only FDA-approved reversal agent for factor Xa inhibitors, was successful in mitigating bleeding events associated with that class of anticoagulants, researchers reported Feb. 7 in the New England Journal of Medicine.

Thumbnail

Oral antibiotics on par with IV delivery for endocarditis

A Danish study of 400 patients with infective endocarditis has concluded oral delivery of antibiotics to treat the disease yields similar safety and efficiency as administering the drugs intravenously.

Thumbnail

Almost 25% of HFrEF patients prescribed drugs that could worsen their condition

Nearly a quarter of adults living with heart failure with reduced ejection fraction (HFrEF) are prescribed at least one pharmaceutical that could exacerbate their condition, according to a study published in the American Journal of Cardiology Feb. 10.